Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad082 ↗Kurz gefasst
Kommentar in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Fabrizio Martora und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biosimilar Pharmaceuticals, Mevalonate Kinase Deficiency, Psoriasis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
This letter comments on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Fabrizio Martora, Claudio Marasca, Teresa Battista
Zitieren
APA
Martora, F., Fabbrocini, G., Marasca, C., Battista, T., & Megna, M. (2023). Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad082
Vancouver
Martora F, Fabbrocini G, Marasca C, Battista T, Megna M. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad082
BibTeX
@article{Martora2023,
author = {Martora, Fabrizio and Fabbrocini, Gabriella and Marasca, Claudio and Battista, Teresa and Megna, Matteo},
title = {Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad082}
}
EUVIMED